Arzneimittelforschung 2008; 58(4): 193-198
DOI: 10.1055/s-0031-1296492
Immunomodulators · Immunostimulants · Immunosuppressants
Editio Cantor Verlag Aulendorf (Germany)

Bio equivalence of Two Subcutaneous Pharmaceutical Products of Interferon Beta la

Guillermo Di Girolamo
1   Facultad de Ciencias Médicas, Universidad Favaloro, Buenos Aires, Argentina
Marcelo A Kauffman
2   Bio Sidus SA., Buenos Aires, Argentina
Eliseo González
3   Centro de Diagnóstico Molecular SA., Buenos Aires, Argentina
Mariana Papouchado
2   Bio Sidus SA., Buenos Aires, Argentina
Alejandra Ramirez
2   Bio Sidus SA., Buenos Aires, Argentina
Guillermo Keller
1   Facultad de Ciencias Médicas, Universidad Favaloro, Buenos Aires, Argentina
César Carbonetto
2   Bio Sidus SA., Buenos Aires, Argentina
Susana Dabsys
2   Bio Sidus SA., Buenos Aires, Argentina
Alejandro Vidal
2   Bio Sidus SA., Buenos Aires, Argentina
Aída Sterin-Prync
2   Bio Sidus SA., Buenos Aires, Argentina
Roberto A. Diez
2   Bio Sidus SA., Buenos Aires, Argentina
› Institutsangaben
Weitere Informationen


15. Dezember 2011 (online)


Blastoferon®, in the following referred to as the test product, is a pharmaceutical product of interferon beta la (CAS 220581-49-7) currently marketed as a biosimilar to the innovator interferon beta la product (referred to as the reference product). Pharmacokinetics and pharmacodynamics assays are critically relevant to demonstrate similarity between biopharma-ceuticals. The aims of the present study were to investigate the bioavailability (BA) of the test product (either absolute or relative to the innovator product) and to compare the extent of increase of neopterin concentration following administration of either product. Two studies were performed: initially, an absolute BA assay with i.V. and s.c. injection of test product to 12 healthy subjects. Second, a formal relative BA study with s.c. injections of 88 μg of both products to 24 healthy volunteers. Blood samples for pharmacokinetic and pharmacodynamic profiling were drawn at different intervals after injection. Interferon beta (IFNB) concentrations were determined by ELISA. In the absolute BA study, a single s.c. dose of 44 μg of the test product resulted in a median bioavailable fraction of 29%, a median Tmax of 4 h (4–6) and a Cmax of 3.69 (3.27–4.41) IU · ml−1.

In the relative BA study, values for the test product were: median Tmax of 3 h (2–18), Cmax of 5.39 (4.99–6.31) IU · ml−1, AUC(0–72) of 142.86 (134.16–190.15) IU 9 h ml1 and AUC(0–infinity) of 190.95 (174.23–303.13) IU 0 h ml−1. The corresponding values for the innovator product were: Tmax of 3h (l-24),Cmax of 4.44 (4.12–5.40) IU I ml−1, AUC(0–72) of 128.77 (121.18–170.92) IU 7 h ml−1 and AUC(0-infinity) of 192.61 (183.04–286.46) IU 8 h h ml−1. The Alicia ratio was 111% (CI 90%: 106–116), the AUC(0-infinity) was 99% (CI 90%: 92–107) and the Cmax ratio was 121% (CI 90%: 112–131). IFNBla increased neopterin levels in both studies. Both products induced side-effects commonly reported for IFN with no serious adverse events. This study presents pharmacokinetics parameters of the test product and demonstrates similar bioavailability of IFNBla for both pharmaceutical products.

  • Literature

  • 1 Jacobs L, Salazar AM, Herndon R, Reese PA, Freeman A, Jozefowicz R et al. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis. Results of a multicenter, double-blind study. Arch Neurol. 1987; Jun 44 (6) 589-595
  • 2 Bermel RA, Rudick RA. Interferon-beta Treatment for Multiple Sclerosis. Neurotherapeutics. 2007; Oct 4 (4) 633-646
  • 3 Neuhaus O, Kiesseier B, Hartung H. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J Neurol Sci. 2007; Aug 15 259 (l–2) -27–37
  • 4 Gruber R. [Comparison of pharmacokinetic and pharmacodynamic data of interferon-beta la preparations after intramuscular and subcutaneous administration]. Arzneimittel-Forschung (Drug Research). 1998; Oct 48 (10) 1043-1046
  • 5 Mager D, Neuteboom B, Efthymiopoulos C, Munafo A, Jusko W. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta la in monkeys. J Pharmacol Exp Ther. 2003; Jul 306 (1) 262-270
  • 6 Rogge MC, Simonian NA, Jones WE. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-la after intramuscular and subcutaneous administration. Eur J Neurol. 1999; May 6 (3) 375-377
  • 7 Buchwalder P, Buclin I, Trinchard I, Munafo A, Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta la in healthy vounteers. J Interferon Cytokine Res. 2000; Oct 20 (10) 857-866
  • 8 Kappos L, Achtnichts L, Dahlke F, Kuhle J, Naegelin Y, Sand-brink R et al. Genomics and proteomics: role in the management of multiple sclerosis. J Neurol. 2005; Sep 252 Suppl (3) iii21-iii27
  • 9 Hovanessian AG, Justesen J. The human 2’-5’ oligoadeny-late synthetase family: unique interferon-inducible enzymes catalyzing 2’-5’ instead of 3’-5’ phosphodiester bond formation. Biochimie. 2007; Jun-Jul 89 (6–7) 779-788
  • 10 Casoni F, Merelli E, Bedin R, Sola P, Bertolotto A, Faglioni P. Is serum neopterin level a marker of responsiveness to interferon beta-la therapy in multiple sclerosis?. Acta Neurol Scand. 2004; Jan 109 (1) 61-65
  • 11 Scagnolari C, Duda P, Bagnato F, De Vito G, Alberelli A, Lavolpe V et al. Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. J Neurol. 2007; May 254 (5) 597-604
  • 12 Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2007; Sep 14
  • 13 Morgan B, Tarter T. Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer. J Urol. 2001; December 166 (6) 2311-2312
  • 14 Tothfalusi L, Endrenyi L, Midha KK. Scaling or wider bio-equivalence limits for highly variable drugs and for the special case of C(max). Int J Clin Pharmacol Ther. 2003; May 41 (5) 217-225
  • 15 Tothfalusi L, Endrenyi L, Midha KK, Rawson MJ, Hubbard JW. Evaluation of the bioequivalence of highly-variable drugs and drug products. Pharm Res. 2001; Jun 18 (6) 728-733
  • 16 Boddy AW, Snikeris FC, Kringle RO, Wei GC, Oppermann JA, Midha KK. An approach for widening the bioequivalence acceptance limits in the case of highly variable drugs. Pharm Res. 1995; Dec 12 (12) 1865-1868
  • 17 Brearley C, Jaber A, Bertolino M, Priestley A, Seiberling M. Assessment of the safety, tolerability, and PK/PD properties of two new formulations of subcutaneously administered IFN-betala: a double-blind, placebo-controlled comparison with the currently available formulation. Int J Clin Pharmacol Ther. 2007; Jun 45 (6) 307-318
  • 18 Hao K, Cao YG, Zhao YN, Mao GG, Liu XQ, Wang GJ. Bioequivalence of two tablet formulations of helicidum ad-minstered in single dose to healthy Chinese volunteers. Arzneimittel-Forschung (Drug Research). 2007; 57 (8) 522-525
  • 19 Boonleang J, Panrat K, Tantana C, Krittathanmakul S, Jinta-pakorn W. Bioavailability and pharmacokinetic comparison between generic and branded azithromycin capsule: a randomized double-blind 2-way crossover in healthy male Thai volunteers. Clin Ther. 2007; Apr 29 (4) 703-710
  • 20 Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab. 2002; Apr 3 (2) 175-187
  • 21 Sterin-Prync A, Yankilevich P, Barrero P, Bello R, Marangu-nich L, Vidal A et al. Two recombinant human interferon-beta la pharmaceutical preparations produce a similar transcriptional response by whole genome microarray analysis. Int J Clin Pharmacol Ther. 2008; in press
  • 22 Rozen T, Swidan SZ. Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine. Headache. 2007; Jul-Aug 47 (7) 1050-1055
  • 23 Jin S, Kawanokuchi J, Mizuno T, Wang J, Sonobe Y, Takeuchi H et al. Interferon-beta is neuroprotective against the toxicity induced by activated microglia. Brain Res. 2007; Nov 7 1179: 140-146